Tumor Neoantigens: When Too Much of a Good Thing Is Bad
- PMID: 31715129
- DOI: 10.1016/j.ccell.2019.10.009
Tumor Neoantigens: When Too Much of a Good Thing Is Bad
Abstract
Immunotherapy has been the most effective in tumors with high mutational burden. However, a recent study in Cell by Wolf et al. demonstrates that high intratumor heterogeneity (ITH) for cancer neoantigens paradoxically attenuates anti-tumor immune responses, suggesting a need to quantify ITH to improve patient selection for checkpoint blockade therapy.
Copyright © 2019 Elsevier Inc. All rights reserved.
Comment on
-
UVB-Induced Tumor Heterogeneity Diminishes Immune Response in Melanoma.Cell. 2019 Sep 19;179(1):219-235.e21. doi: 10.1016/j.cell.2019.08.032. Epub 2019 Sep 12. Cell. 2019. PMID: 31522890 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
